companies

MVision AI

Founded 2017
Employees 35+
Primary contact
Paciuksenkatu 29
6th floor
00270 Helsinki
Finland
+358 (0) 40 5489 229
Links
https://www.mvision.ai/
Diseases & Conditions
Sections
Technologies
MVision AI provides is a cloud-based software service provider for radiotherapy treatment planning. Its AI-powered automatic segmentation tool helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. MVision's deep learning model produces consistent contouring in minutes while maintaining the highest standards of quality for every patient, every time. As of March 2022, the company's Guideline-Based Segmentation solution has been used for treating more than 100,000 cancer patients in 14 countries.
Select partners: DTA S.L, OncoMed-Solutions, Xiel, intellimed, SERES Medical, AQUILAB, YourRad, Medron Medical, Tecnosan.
Founded 2017
Employees 35+
Primary contact
Paciuksenkatu 29
6th floor
00270 Helsinki
Finland
+358 (0) 40 5489 229
Links
https://www.mvision.ai/
Diseases & Conditions
Sections
Technologies

Funding 💰

Total $8.3M
Last round 🔗 €5.4M
Post-Seed
March 23, 2023.
Select investors J12 Ventures, Voima Ventures, Icebreaker VC, Nuard Ventures

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Tapping into a global challenge: The aging population is increasing the prevalence of cancer. The International Agency for Research on Cancer estimates that the number of patients treated with radiotherapy will grow to 29 million by 2040. 🔗
  • Solving a problem: With manual treatment planning, patients often have to wait 2-3 weeks before beginning treatment. In contrast, with MVision AI's automation, the aim is to enable same-day treatment.
  • It works: MVision AI's technology has been used to treat more than 100,000 cancer patients in 14 countries, with most patients originating in Finland, Sweden and the UK. And according to the evaluation by Sociedad Española de Oncologia Radioterapica in Madrid, Spain, MVision AI technology has significantly contributed to reducing contouring time and enhancing patient care by shortening waiting times. After implementing MVision AI, it was reported that 44% of all breast cancer scans were ready to be planned on the same day. Without MVision AI, only 10% of the scans were ready to be planned on the same day. 🔗
  • Peer-reviewed: In November 2020, the company published its first peer-reviewed paper. The retrospective multicenter study proves that using a general deep learning-based automated segmentation tool for CT images indeed saves time and improves consistency. 🔗

Video ▶️

In the news 📰

MVision AI raises €5.4M for AI-powered Cancer treatment planning platform
March 25, 2023

Quotes 💬

“
MVision AI has arguably built the world's best AI models to support oncologists with automated segmentation for radiotherapy to treat cancer. Hence, saving hospital costs and reducing waiting time for patients in need. We're excited to back Mahmudul and his team as they scale the company, soon helping patients in need around the globe.
— Luca Banderet, Partner at J12 Ventures 🔗
“
We were impressed by the number of patients that have already been successfully treated with the help of MVision AI technology. Automating treatment processes enables faster care and more time to focus on patient care and human interactions that technology cannot replace.
— Pontus Stråhlman, Partner at Voima Ventures 🔗
“
We were immediately impressed by the quality and consistency of MVision's AI auto-segmentation. It fits seamlessly and transparently into our workflow, saving many planners and physicians time. This AI-based auto-segmentation model covers the whole body - a hugely appreciated time saver for our busy clinical team.
— Chihray Liu, PhD, DABR, FAAPM Professor and Chief of Physics-Gainesville Department of Radiation Oncology, University of Florida 🔗
Last update: March 28, 2023